Genfit S.A. (OTCMKTS:GNFTF – Get Free Report) traded up 3.4% during trading on Wednesday . The stock traded as high as $16.50 and last traded at $16.50. 600 shares were traded during mid-day trading, an increase of 35% from the average daily volume of 445 shares. The stock had previously closed at $15.95.
Genfit Stock Performance
The business has a fifty day moving average price of $13.07 and a 200 day moving average price of $10.91.
About Genfit
Genfit is a clinical‐stage biopharmaceutical company headquartered in Lille, France, specializing in the development of innovative therapies and diagnostics for liver and metabolic diseases. The company’s research and development efforts are primarily focused on non‐alcoholic steatohepatitis (NASH), a progressive liver disorder with significant unmet medical needs. Genfit’s lead therapeutic candidate, elafibranor, is designed to target key pathways involved in inflammation, fibrosis and lipid metabolism, positioning it as a potential treatment for patients with NASH and associated metabolic complications.
In addition to its therapeutic pipeline, Genfit has established a diagnostic arm centered on NIS4®, a proprietary blood‐based test that leverages transcriptomic biomarkers to enable earlier and more accurate detection of liver fibrosis in patients at risk for NASH.
Recommended Stories
- Five stocks we like better than Genfit
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
- Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.
